Targeting MYC/MYCN-driven Transcriptional Amplification in Pediatric Cancer |
Dana-Farber Cancer Institute / Rani George, M.D., Ph.D. |
Innovation Grants |
2014 |
Massachusetts |
Identification of Novel Treatment Targets by Exploring the Interaction of Rhabdomyosarcoma-Associated Oncogenes with Cellular Context in a Mouse Model of Rhabdomyosarcoma |
Dana-Farber Cancer Institute / Simone Hettmer |
Young Investigator Grants |
2010 |
Massachusetts |
The Role of ARID1A in Neuroblastoma Pathogenesis |
Dana-Farber Cancer Institute / Hui Shi, PhD |
Young Investigator Grants |
2016 |
Massachusetts |
Resistance and Develop Improved Treatments for Relapsed/refractory Pediatric ALL |
Dana-Farber Cancer Institute / Elizabeth Townsend, PhD |
Young Investigator Grants |
2016 |
Massachusetts |
Web-Based Cognitive-Behavioral Treatment for Insomnia in Adolescent Cancer Survivors |
Dana-Farber Cancer Institute / Eric Zhou, PhD |
Psychosocial Grants |
2016 |
Massachusetts |
Targeted Hyperactivation of PI3K/AKT in B-cell malignancies |
Dana-Farber Cancer Institute / Vishal Khairnar, PhD |
Young Investigator Grants |
2019 |
Massachusetts |
Identification of New Therapeutic Targets in Pediatric Acute Lymphoblastic Leukemia Through Mosaic Trisomy and Aneuploidy-Based Synthetic Lethality Screens |
Dana-Farber Cancer Institute / David Pellman |
Innovation Grants |
2010 |
Massachusetts |
Inhibition of translation initiation as a novel therapeutic strategy against MYCN-amplified neuroblastoma |
Dana-Farber Cancer Institute / Rani George, MD, PhD |
Innovation Grants |
2022 |
Massachusetts |
Targeting symmetric division in pediatric cancers |
Dana-Farber Cancer Institute / Rosalind Segal, MD/PhD |
Innovation Grants |
2019 |
Massachusetts |
Epigenetic regulation of genomic instability and its therapeutic implications in T-cell acute lymphoblastic leukemia |
Dana-Farber Cancer Institute / Birgit Knoechel, MD/PhD |
Innovation Grants |
2019 |
Massachusetts |